ArticleCurrent cancer reports2020
Financial distress among breast cancer survivors.
Article in Current cancer reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 4 syntheses or guidelines pooled it, 26 citations in OpenAlex.
- Assessing Financial Toxicity in Cancer: A Global Systematic Review and Meta-Analysis Using an Asset Framework.Cancer medicine · 2026Pooled it
- Health Information Needs of Breast Cancer Survivors: An Umbrella Review.The breast journal · 2024Pooled it
- Evaluation of financial toxicity and associated factors in female patients with breast cancer: a systematic review and meta-analysis.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2023Pooled it
- Financial toxicity experienced by patients with breast cancer-related lymphedema: a systematic review.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2023Pooled it
- Income, race, and cardiovascular disease in female breast cancer survivors: evidence of moderated socioeconomic protection in the National Health Interview Survey (NHIS) 2019-2022.Journal of cancer survivorship : research and practice · 2026Article
- Persistent adverse effects of cancer treatments on mental health, fatigue, and sleep disturbances in breast cancer survivors.BMC women's health · 2026Article
- Comorbidity patterns and risk of breast cancer: a case-control study exploring interaction with BMI using latent class analysis.Frontiers in oncology · 2026Article
- Factors Contributing to Late Breast Cancer Diagnosis: A Qualitative Study on the Patient's Perspective in Tanzania.BMC women's health · 2025Article
- Baseline Distress and Effectiveness of Survivor Video Narratives on Cancer-Associated Distress in Botswana: A Pilot Study.JCO global oncology · 2025Article
- Non-monetary burdens of out-of-pocket costs incurred by patients and caregivers for medical care: a scoping review.BMJ open · 2025Article
- The Role of Social Support in Buffering the Financial Toxicity of Breast Cancer: A Qualitative Study of Patient Experiences.Cancers · 2025Article
- Cancer cost-related subjective financial distress among breast cancer: a scoping review.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024Article
- Article
- Breast cancer survivorship needs: a qualitative study.BMC cancer · 2024Article
- Incidence and risk factors for psychological distress in adult female patients with breast cancer: a systematic review and meta-analysis.Frontiers in psychiatry · 2024Review
- A hermeneutic phenomenological study on the disease experience among young women with breast cancer.Asia-Pacific journal of oncology nursing · 2023Article
- Factors associated with financial toxicity in patients with breast cancer in Japan: a comparison of patient and physician perspectives.Breast cancer (Tokyo, Japan) · 2023Article
- Evolving Perceptions, Utilization, and Real-World Implementation Experiences of Oncology Monoclonal Antibody Biosimilars in the USA: Perspectives from Both Payers and Physicians.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
aimsthere has been an increasing awareness of the potential for oncology care to result in long-term financial burdens and financial toxicity. Patients who report cancer-related financial problems or high costs are more likely to forgo or delay prescription medications and medical care. MATERIALS AND
methodswe examined financial distress using data from a survey of 164 breast cancer survivors who had completed primary therapy for the disease. KEY
findingsamong respondents, 8.6% (13 of 151) reported that "being less able to provide for the financial needs of their family" was as a severe problem; 14.4% (22 of 153) reported "difficulty in meeting medical expenses" was a severe problem; and 8.4% (13 of 154) reported that "no money for cost of or co-payment for medical visits" was a severe problem. About 8.4% (13 of 154) of the respondents reported that "no money for cost of or co-payment for medicine" was a severe problem. In logistic regression analysis, younger age and lower household income were significant predictors of financial distress. In multiple linear regression analysis, younger age and lower household income were significant predictors of financial distress. SIGNIFICANCE: financial toxicity remains a major issue in breast cancer care. Efforts are needed to ensure patients experiencing high levels of financial toxicity are able to access recommended care. In addition, patients should talk with their providers about the costs of oncology care and about opportunities to reduce costs while maintaining high quality of care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.